- Home
- EDTK vs BOLT Comparison
EDTK vs BOLT Comparison
Compare EDTK & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- BOLT
- Stock Information
- Founded
- EDTK 2013
- BOLT 2015
- Country
- EDTK China
- BOLT United States
- Employees
- EDTK N/A
- BOLT N/A
- Industry
- EDTK Other Consumer Services
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- BOLT Health Care
- Exchange
- EDTK Nasdaq
- BOLT Nasdaq
- Market Cap
- EDTK 14.3M
- BOLT 16.8M
- IPO Year
- EDTK 2020
- BOLT 2021
- Fundamental
- Price
- EDTK $0.93
- BOLT $6.19
- Analyst Decision
- EDTK
- BOLT Buy
- Analyst Count
- EDTK 0
- BOLT 3
- Target Price
- EDTK N/A
- BOLT $50.00
- AVG Volume (30 Days)
- EDTK 8.7K
- BOLT 18.8K
- Earning Date
- EDTK 08-18-2025
- BOLT 08-12-2025
- Dividend Yield
- EDTK N/A
- BOLT N/A
- EPS Growth
- EDTK N/A
- BOLT N/A
- EPS
- EDTK N/A
- BOLT N/A
- Revenue
- EDTK $624,365.00
- BOLT $3,638,000.00
- Revenue This Year
- EDTK N/A
- BOLT N/A
- Revenue Next Year
- EDTK N/A
- BOLT $24.14
- P/E Ratio
- EDTK N/A
- BOLT N/A
- Revenue Growth
- EDTK N/A
- BOLT N/A
- 52 Week Low
- EDTK $0.80
- BOLT $5.20
- 52 Week High
- EDTK $1.27
- BOLT $15.60
- Technical
- Relative Strength Index (RSI)
- EDTK 54.77
- BOLT 52.70
- Support Level
- EDTK $0.87
- BOLT $5.68
- Resistance Level
- EDTK $0.95
- BOLT $6.40
- Average True Range (ATR)
- EDTK 0.05
- BOLT 0.30
- MACD
- EDTK 0.01
- BOLT 0.09
- Stochastic Oscillator
- EDTK 100.00
- BOLT 79.81
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.